Cidara Therapeutics (NASDAQ:CDTX – Get Free Report) and Invivyd (NASDAQ:IVVD – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, earnings, analyst recommendations, valuation and profitability.
Valuation & Earnings
This table compares Cidara Therapeutics and Invivyd”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Cidara Therapeutics | $1.28 million | 182.05 | -$22.93 million | ($30.09) | -0.61 |
| Invivyd | $25.38 million | 3.02 | -$198.64 million | ($1.44) | -0.44 |
Profitability
This table compares Cidara Therapeutics and Invivyd’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Cidara Therapeutics | -289.05% | -69.64% | -33.73% |
| Invivyd | N/A | -155.33% | -114.88% |
Analyst Ratings
This is a summary of recent ratings and recommmendations for Cidara Therapeutics and Invivyd, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Cidara Therapeutics | 0 | 0 | 7 | 2 | 3.22 |
| Invivyd | 0 | 0 | 3 | 1 | 3.25 |
Cidara Therapeutics currently has a consensus price target of $39.57, indicating a potential upside of 113.90%. Invivyd has a consensus price target of $7.52, indicating a potential upside of 1,076.32%. Given Invivyd’s stronger consensus rating and higher possible upside, analysts plainly believe Invivyd is more favorable than Cidara Therapeutics.
Insider & Institutional Ownership
35.8% of Cidara Therapeutics shares are held by institutional investors. Comparatively, 70.4% of Invivyd shares are held by institutional investors. 3.9% of Cidara Therapeutics shares are held by company insiders. Comparatively, 25.4% of Invivyd shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Volatility & Risk
Cidara Therapeutics has a beta of 0.86, suggesting that its share price is 14% less volatile than the S&P 500. Comparatively, Invivyd has a beta of 0.4, suggesting that its share price is 60% less volatile than the S&P 500.
Summary
Invivyd beats Cidara Therapeutics on 8 of the 15 factors compared between the two stocks.
About Cidara Therapeutics
Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.
About Invivyd
Invivyd, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19. The company also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.
Receive News & Ratings for Cidara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cidara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
